Achillion Pharmaceuticals Inc (ACHN)

8.54
NASDAQ : Health Care
Prev Close 8.60
Day Low/High 8.41 / 8.73
52 Wk Low/High 5.57 / 10.95
Avg Volume 1.34M
Exchange NASDAQ
Shares Outstanding 136.68M
Market Cap 1.18B
P/E Ratio 78.18
Div & Yield N.A. (N.A)

Latest News

ACHN August 26th Options Begin Trading

ACHN August 26th Options Begin Trading

Investors in Achillion Pharmaceuticals Inc. saw new options begin trading today, for the August 26th expiration.

Achillion Pharmaceuticals (ACHN) Stock Up, JMP Upgrades

Achillion Pharmaceuticals (ACHN) Stock Up, JMP Upgrades

Achillion Pharmaceuticals (ACHN) stock rating was increased this morning to 'market outperform' at JMP as the firm believes the company's factor D program is a 'game changer.'

Analysts' Actions -- First Solar, Qualcomm, Red Hat, Zions and More

Analysts' Actions -- First Solar, Qualcomm, Red Hat, Zions and More

Here are Thursday's top research calls, including an upgrade for Zions, and downgrades for First Solar, Qualcomm and Red Hat.

Interesting ACHN Put And Call Options For August 5th

Interesting ACHN Put And Call Options For August 5th

Investors in Achillion Pharmaceuticals Inc. saw new options begin trading today, for the August 5th expiration.

Achillion Pharmaceuticals (ACHN) Weak On High Volume Today

Achillion Pharmaceuticals (ACHN) Weak On High Volume Today

Trade-Ideas LLC identified Achillion Pharmaceuticals (ACHN) as a weak on high relative volume candidate

Achillion Reports 2015 Fourth Quarter And Year-End Financial Results

Achillion Reports 2015 Fourth Quarter And Year-End Financial Results

Strong Balance Sheet to Support Planned 2016 Clinical Expansion of Complement Factor D Platform

Achillion Initiates Phase 1 Study Of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor

Achillion Initiates Phase 1 Study Of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor

Company's Proprietary Complement Platform Focuses on Advancing Factor D Inhibitor Drug Candidates That Could Treat Ultra-Rare Diseases Such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Other Complement-Mediated Diseases

Achillion Pharmaceuticals is Now Oversold (ACHN)

Achillion Pharmaceuticals is Now Oversold (ACHN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Achillion Pharmaceuticals (ACHN) Weak On High Volume

Achillion Pharmaceuticals (ACHN) Weak On High Volume

Trade-Ideas LLC identified Achillion Pharmaceuticals (ACHN) as a weak on high relative volume candidate

Achillion Pharmaceuticals (ACHN) Flagged As Strong On High Volume

Achillion Pharmaceuticals (ACHN) Flagged As Strong On High Volume

Trade-Ideas LLC identified Achillion Pharmaceuticals (ACHN) as a strong on high relative volume candidate

Trade-Ideas: Achillion Pharmaceuticals (ACHN) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Achillion Pharmaceuticals (ACHN) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Achillion Pharmaceuticals (ACHN) as a strong on high relative volume candidate

Achillion Pharmaceuticals (ACHN) Is Today's Dead Cat Bounce Stock

Achillion Pharmaceuticals (ACHN) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Achillion Pharmaceuticals (ACHN) as a "dead cat bounce" (down big yesterday but up big today) candidate

Lilly's Diabetes Drug Makes It a Turner Medical Fund Pick

Lilly's Diabetes Drug Makes It a Turner Medical Fund Pick

John Fraunces, portfolio manager for the Turner Medical Sciences Long/Short Fund, said Lilly has merited Wall Street's praise.

Achillion Pharmaceuticals (ACHN) Stock Has 40% Potential Upside

Achillion Pharmaceuticals (ACHN) Stock Has 40% Potential Upside

We like the long side of Achillion Pharmaceuticals (ACHN).

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABBV, ACHN, DBD, DFS, GBLI, IFON, JOBS, LCUT, LOJN, NTL, RAIL, STT, TTWO, UVV Downgrades: AAWW, ASPN, BCH, ECPG, ETE, GSL, LPG, LXU, MW, MYRG, NTK, PCYO, PSDV, SEB, TNGO Initiations: RWLK, TPH, VTAE Read on to get TheStreet Quant Ratings' detailed report: